Zepbound

News

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Lilly uses Oscars ad to warn about 'untested' GLP-1s

Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

High-dose semaglutide ramps up weight loss, says Novo

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

Patient using a positive airway pressure mask

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.

Novo Nordisk follows Lilly into DTC obesity drug market

Lilly uses Oscars ad to warn about 'untested' GLP-1s

Lilly launches discounted high-strength Zepbound vials in US

High-dose semaglutide ramps up weight loss, says Novo

Lilly trims sales forecast on weaker obesity/diabetes growth

Lilly grabs first-ever FDA nod for a sleep apnoea drug

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Zepbound

Editor's Picks